Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit ...

New two- and three-year EPCORE® NHL-2 follow-up data evaluating epcoritamab in combination with standard of care regimens demonstrate remission in patients with DLBCL and FLLatest EPCORE DLBCL-3 trial ...

Patients aged 60-75 treated with Orca-T and a reduced intensity conditioning regimen (RIC) experienced low incidence of acute and chronic GvHD with low rates of disease relapseResults also highlight ...

Data presented was selected for ASH’s exclusive program to highlight the most impactful research submitted for this year’s meetingReal-world data reinforces the value of durable, one-time gene ...

Data from pivotal studies of CASGEVY in children ages 5-11 years with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrates the transformative potential of the therapy in ...

Key HighlightsMotixafortide effectively mobilized sufficient hematopoietic stem cells (HSCs) in patients with sickle cell disease enabling accelerated access to gene therapies90% (9 of 10) of patients ...

Authorized distribution partnership brings VHF's industry-leading milling technology to Shinoda Dental's global customers. SINGAPORE, SG / ACCESS Newswire / December 6, 2025 / Shinoda Dental is a top ...

Study demonstrated early and sustained hematopoietic recovery and transfusion independenceOmisirge is a new and novel transplant option for patients with SAAAdditional manufacturing capacity for ...

The "Mice Model Market - Global Forecast 2025-2032" has been added to ResearchAndMarkets.com's offering.The mice model market is experiencing robust growth, with projected expansion from USD 1.61 ...

The "Allergy Diagnostics and Therapeutics Market Forecast to 2033" has been added to ResearchAndMarkets.com's offering.The global allergy diagnostics and therapeutics market, valued at USD 34.42 ...

Maxim Group LLC is acting as the exclusive Financial Advisor for the transaction PHILADELPHIA, PA / ACCESS Newswire / December 5, 2025 / Medicus Pharma Ltd. (NASDAQ:MDCX) ("Medicus" or the "Company"), ...

Partnership enables ImmunoACT to offer eligible patients a bridge financing plan and value-based offering to access its ...